Notice of Allowability	Application No.	Applicant(s)	
	09/955,407	ROSEN, HUGO R.	
	Examiner	Art Unit	\ <u>\</u>
	Celine X Qian	1636	
The MAILING DATE of this communicating I claims being allowable, PROSECUTION ON THE ME erewith (or previously mailed), a Notice of Allowance (POTICE OF ALLOWABILITY IS NOT A GRANT OF PATE of the Office or upon petition by the applicant. See 37 CF	RITS IS (OR REMAINS) CLOSED in TOL-85) or other appropriate comming TENT RIGHTS. This application is s	this application. If not including this application will be mailed in due	ded e course. THIS
. $igotimes$ This communication is responsive to ${\it the\ amendments}$	ent filed on 7/20/04.		
☐ The allowed claim(s) is/are <u>35-40</u> .			
. $igotimes$ The drawings filed on <u>12 September 2001</u> are acc	epted by the Examiner.		
☐ Acknowledgment is made of a claim for foreign p a) ☐ All b) ☐ Some* c) ☐ None of the:		or (f).	
 Certified copies of the priority docume 			
2. Certified copies of the priority documents			
3. Copies of the certified copies of the pri	-	I in this national stage applic	ation from the
International Bureau (PCT Rule 17.2(a	,,		
* Certified copies not received:	uschwarg zu gür i		
Applicant has THREE MONTHS FROM THE "MAILING noted below. Failure to timely comply will result in ABAITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE	NDONMENT of this application.	a reply complying with the re	equirements
5. A SUBSTITUTE OATH OR DECLARATION must be INFORMAL PATENT APPLICATION (PTO-152) wi			NOTICE OF
6. CORRECTED DRAWINGS (as "replacement shee	ts") must be submitted.		
(a) ☐ including changes required by the Notice of Dr	raftsperson's Patent Drawing Review	(PTO-948) attached	

(b) I including changes required by the attached Examiner's Amendment / Comment or in the Office action of

each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of

7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

1) hereto or 2) to Paper No./Mail Date

Paper No./Mail Date

1. Notice of References Cited (PTO-892)

Paper No./Mail Date

of Biological Material

2. Notice of Draftperson's Patent Drawing Review (PTO-948)

4.

Examiner's Comment Regarding Requirement for Deposit

3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),

5. ☐ Notice of Informal Patent Application (PTO-152)6. ☐ Interview Summary (PTO-413),

Paper No./Mail Date _____.
7. ⊠ Examiner's Amendment/Comment

8.

Examiner's Statement of Reasons for Allowance

9. Other _____.

ANNE-MARIE FALK, PH.D. PRIMARY EXAMINER

Attachment(s)

Application/Control Number: 09/955,407

Art Unit: 1636

EXAMINER'S AMENDMENT

The after final amendment filed on 7/20/04 has been entered.

An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment which places this application in condition for allowance. During a telephone conversation conducted on 8/3/04, Applicant's representative Susan Alpert Siegel authorized the Director to charge Deposit Account No. 02-4550 the required fee for the extension of one month and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claim 35: A method of identifying a preferred liver transplant donor, comprising determining in both alleles of an individual the presence or absence of a preferred genotype at a polymorphic site, wherein said preferred genotype is a guanine (G) at position -380 in a gene encoding tumor necrosis factor α (TNF- α) relative to the transcription start site, and measuring the activity of said TNF- α , [and wherein said preferred genotype is associated with decreased activity of tumor necrosis factor α (TNF- α),] wherein the presence of said preferred genotype is associated with a decrease in the activity of TNF- α and indicates that said individual is a preferred liver transplant donor.

Claim 36: A method for selecting a preferred liver for transplantation, comprising (a) determining in one or more potential liver donors the presence or absence of a preferred genotype at a polymorphic site, and measuring the activity of TNF-a, [said preferred genotype

Application/Control Number: 09/955,407 Page 3

Art Unit: 1636

associated with altered activity of tumor necrosis factor- α (TNF- α),] wherein said preferred genotype is a guanine (G) at position –380 relative to the transcription start site in both alleles in a gene encoding TNF- α ; (b) harvesting a liver, or functional portion thereof, having the preferred genotype associated with decreased TNF- α activity; thereby selecting a preferred liver for transplantation.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine Qian, Ph.D.

Anne-Marie Falk, PH.D